Especially, besides RFS, reduced BTG2 also indicated poor overall survival (OS) and distant metastasis free survival (DMFS) in breast cancer patients who were classified as luminal A. Therefore, we propose BTG2 could act as a prognostic biomarker for breast cancer, especially for the subtype of luminal A. This evidence concerns the gene BTG2 and breast cancer.